Search results: Found 2

Listing 1 - 2 of 2
Sort by
Soft Tissue and Bone Sarcoma

ISBN: 9783906980461 9783906980584 Year: Pages: 156 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Added to DOAB on : 2015-01-12 11:17:42
License:

Loading...
Export citation

Choose an application

Abstract

Soft tissue and bone sarcomas disproportionately affect children, adolescents, and young adults. Although considered a rare disease, sarcomas continue to have a devastating effect on these patients and their loved ones, and their impact on our society far exceed their relatively low prevalence. Because of its rarity and heterogeneity, clinical decision making on management of sarcomas are often individualized and without a consensus treatment strategy. Furthermore, research to improve clinical outcomes are particularly challenging as sizeable studies are hard to produce. By improving our knowledge about the molecular biology of sarcomas, we hope to identify new treatment strategies and targets for further drug development. [...]

Drug-Diagnostics Co-Development in Oncology

Author:
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889193325 Year: Pages: 111 DOI: 10.3389/978-2-88919-332-5 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General) --- Therapeutics --- Science (General)
Added to DOAB on : 2016-03-10 08:14:32
License:

Loading...
Export citation

Choose an application

Abstract

The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area.

Listing 1 - 2 of 2
Sort by
Narrow your search

Publisher

Frontiers Media SA (1)

MDPI - Multidisciplinary Digital Publishing Institute (1)


License

CC by (2)


Language

english (2)


Year
From To Submit

2014 (2)